3 Drugs Stocks On The Rise

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 15 points (0.1%) at 17,122 as of Wednesday, Aug. 27, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,632 issues advancing vs. 1,319 declining with 192 unchanged.

The Drugs industry currently sits up 0.2% versus the S&P 500, which is unchanged. A company within the industry that increased today was Grifols ( GRFS), up 2.1%. On the negative front, top decliners within the industry include Bristol-Myers Squibb Company ( BMY), down 1.0%, and Celgene ( CELG), down 0.7%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. GlaxoSmithKline ( GSK) is one of the companies pushing the Drugs industry higher today. As of noon trading, GlaxoSmithKline is up $0.41 (0.8%) to $48.67 on average volume. Thus far, 1.3 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $48.56-$48.82 after having opened the day at $48.62 as compared to the previous trading day's close of $48.26.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $115.6 billion and is part of the health care sector. Shares are down 9.6% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst who rates GlaxoSmithKline a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

These Stocks Pay You to Own Them

Nascar Champ Danica Patrick--'I'm Not That Into Cars'

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Hikma Sinks on Advair Generic Concerns

Shire Gains as it Seeks European Approval For Dry Eye Treatment